LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Lista de Ações・Twist Bioscience Corp

Twist Bioscience Corp

Fechado

SetorSaúde

58.5 -1.76

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

57.66

Máximo

59.42

Indicadores-chave
By Trading Economics
Rendimento	-14M -44M
Vendas	7M 111M
EPS	-0.597
Margem de lucro	-39.761
Funcionários	979
EBITDA	-16M -40M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+6.55% upside

Dividendos
By Dow Jones
Próximos Ganhos	3 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	843M 3.4B
Abertura anterior	60.26
Fecho anterior	58.5

Sentimento de Notícias

By Acuity

17%

83%

23 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

31.56 / 38.6884 Suporte e Resistência

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de mai. de 2026, 23:58 UTC

Ganhos

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 de mai. de 2026, 22:57 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 de mai. de 2026, 23:52 UTC

Ganhos

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 de mai. de 2026, 23:11 UTC

Ganhos

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 de mai. de 2026, 23:06 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 de mai. de 2026, 23:05 UTC

Ganhos

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 de mai. de 2026, 23:04 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 de mai. de 2026, 23:02 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 de mai. de 2026, 23:00 UTC

Conversa de Mercado

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 de mai. de 2026, 22:42 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 de mai. de 2026, 22:33 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 de mai. de 2026, 22:32 UTC

Ganhos

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie: 68% of FY Income From International >MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 de mai. de 2026, 22:29 UTC

Ganhos

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 de mai. de 2026, 22:26 UTC

Ganhos

Macquarie to End Share Buyback Extended in November>MQG.AU

7 de mai. de 2026, 22:25 UTC

Ganhos

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

6.55% parte superior

Previsão para 12 meses

Média 63.43 USD 6.55%

Máximo 70 USD

Mínimo 56 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para Twist Bioscience Corp - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentimento

By Acuity

23 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.